This is the development pipeline As of Oct 27, 2020.
1. Oncology (OPDIVO)
As of Oct 27, 2020
| Product name (Generic name) |
Mechanism | Target disease | Development stage |
Country/ Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F i l i n g |
A p p r o v a l |
|||||
| Opdivo Injection (Nivolmub) | Anti-PD-1 antibody | Melanoma(1st) |
|
JP・KR・TW | In-house (Co-developed with Bristol Myers Squibb) |
||||
| Melanoma (Adjuvant therapy) |
|
JP・KR・TW | |||||||
| Non-small cell lung cancer (2nd～) |
|
JP・KR・TW | |||||||
| Non-small cell lung cancer (1st) |
|
JP | |||||||
|
|
KR・TW | ||||||||
| Renal cell carcinoma (2nd～) |
|
JP・KR・TW | |||||||
| Renal cell carcinoma (1st) |
|
JP・KR・TW | |||||||
| Hodgkin’s lymphoma |
|
JP・KR・TW | |||||||
| Head and neck cancer |
|
JP・KR・TW | |||||||
| Gastric cancer (3rd) |
|
JP・KR・TW | |||||||
| Gastric cancer (1st) |
|
JP | |||||||
|
|
KR・TW | ||||||||
| Malignant pleural mesothelioma |
|
JP | |||||||
| Colorectal cancer（MSI-High） |
|
JP・TW | |||||||
| Esophageal cancer |
|
JP・KR・TW | |||||||
| Gastro-esophageal junction cancer and esophageal cancer |
|
JP・KR・TW | |||||||
| Hepatocellular carcinoma |
|
JP・KR | |||||||
|
|
TW | ||||||||
| Glioblastoma |
|
JP | |||||||
| Urothelial cancer |
|
JP | |||||||
|
|
KR・TW | ||||||||
| Ovarian cancer |
|
JP・KR・TW | |||||||
| Bladder cancer |
|
JP・KR・TW | |||||||
| Cervix carcinoma, Uterine body cancer, Soft tissue sarcoma |
|
JP | |||||||
| Central nervous system lymphoma, Primary Testicular Lymphoma |
|
JP | |||||||
| Pancreatic cancer |
|
JP・KR・TW | |||||||
| Virus positive/negative solid carcinoma |
|
JP・KR・TW | |||||||
| Biliary tract cancer |
|
JP | |||||||
| Prostate cancer |
|
JP・KR・TW | |||||||
2. Oncology (Other than OPDIVO)
As of Oct 27, 2020
| Product name (Generic name) |
Mechanism | Target disease | Development stage |
Country/ Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F i l i n g |
A p p r o v a l |
|||||
| Yervoy Injection★ (Ipilimumab) |
Anti-CTLA-4 antibody | Melanoma |
|
JP・KR・TW | BMS | ||||
| Renal cell carcinoma |
|
JP・KR・TW | |||||||
| Non-small cell lung cancer |
|
JP | |||||||
|
|
KR・TW | ||||||||
| Colorectal cancer（MSI-High） |
|
JP・TW | |||||||
| Head and neck cancer |
|
JP・KR・TW | |||||||
| Gastric cancer |
|
JP・KR・TW | |||||||
| Malignant pleural mesothelioma |
|
JP | |||||||
| Esophageal cancer |
|
JP・KR・TW | |||||||
| Urothelial cancer |
|
JP・KR・TW | |||||||
| Hepatocellular carcinoma |
|
JP・KR・TW | |||||||
| Virus positive/negative solid carcinoma |
|
JP・KR・TW | |||||||
| VELEXBRU Tablet/ (Tirabrutinib) | Bruton‘s tyrosine kinase (BTK) inhibitor | Primary central nervous system lymphoma |
|
JP | In-house | ||||
| Primary macroglobulinemia Lymphoplasmacytic lymphoma |
|
JP | |||||||
| ONO-7643/ (Anamorelin) | Ghrelin mimetic | Cancer cachexia |
|
JP | Helsinn | ||||
| Braftovi Capsule/ (Encorafenib) | BRAF inhibitor | Melanoma (BRAF-mutation positive) |
|
JP | Pfizer | ||||
|
|
KR | ||||||||
| Colorectal cancer (BRAF-mutation positive) |
|
JP | |||||||
|
|
KR | ||||||||
| Mektovi Tablet/ (Binimetinib) | MEK inhibitor | Melanoma (BRAF-mutation positive) |
|
JP | Pfizer | ||||
|
|
KR | ||||||||
| Colorectal cancer (BRAF-mutation positive) |
|
JP | |||||||
|
|
KR | ||||||||
| Kyprolis Injection/ (Carfilzomib) | Proteasome inhibitor | Multiple myeloma |
|
JP | Amgen | ||||
| ONO-7701★ （Linrodostat） |
IDO1 inhibitor | Bladder cancer |
|
JP・KR・TW | BMS | ||||
| ONO-7912 (Devimistat) | Cancer metabolism inhibitor | Pancreatic cancer |
|
KR | Rafael | ||||
|
|
JP | ||||||||
| Acute myeloid leukemia |
|
KR | |||||||
| ONO-4686 ★ | Anti-TIGIT antibody | Solid tumor |
|
JP | BMS | ||||
| ONO-7807★ | Anti-TIM-3 antibody | Solid tumor |
|
JP | BMS | ||||
| ONO-4482★ (Relatlimab) | Anti-LAG-3 antibody | Melanoma |
|
JP | BMS | ||||
| ONO-4483★ (Lirilumab) | Anti-KIR antibody | Solid tumor |
|
JP | BMS | ||||
| ONO-4578★ | PG receptor (EP4) antagonist | Solid tumor |
|
JP | In-house | ||||
| ONO-7475 | Axl/Mer inhibitor | Solid tumor★ |
|
JP | In-house | ||||
| Acute leukemia |
|
US | |||||||
| ONO-7911★ (Bempegaldesleukin) | PEGylated IL-2 | Solid tumor |
|
JP | BMS | ||||
| ONO-7913 (Magrolimab) | Anti-CD47 antibody | Solid tumor |
|
JP | Gilead | ||||
★Combination with Opdivo.
3. Areas other than Oncology
As of Oct 27, 2020
| Product name (Generic name) |
Mechanism | Target disease | Development stage |
Country/ Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F i l i n g |
A p p r o v a l |
|||||
| Coralan Tablet/ ONO-1162 (Ivabradine) | HCN channel blocker | Chronic heart failure |
|
JP | Servier | ||||
| Ongentys Capsule/ ONO-2370 (Opicapone) | Long acting COMT inhibitor | Parkinson’s disease |
|
JP | Bial | ||||
| Onoact Injection (Landiolol hydrochloride) | Short-active selective β1 blocker | Tachyarrhythmia associated with sepsis |
|
JP | In-house | ||||
| Tachyarrhythmia in low cardiac function (Pediatric) |
|
JP | |||||||
| ONO-5704/SI-613 | Hyaluronic acid-NSAID | Osteoarthritis |
|
JP | Seikagaku | ||||
| Enthesopathy |
|
JP | |||||||
| Orencia SC (Abatacept) | T-cell activation inhibitor | Prevention of structural damage of joints in rheumatoid arthritis |
|
JP | BMS | ||||
| Polymyositis/ Dermatomyositis |
|
JP | |||||||
| Velexbru Tablet/ ONO-4059 (Tirabrutinib) | Bruton's tyrosine kinase (BTK) inhibitor | Pemphigus |
|
JP | In-house | ||||
| ONO-7269 | FXIa inhibitor | Cerebral infarction |
|
JP | In-house | ||||
| ONO-4685 | PD-1×CD3 bispecific antibody | Autoimmune disease |
|
JP | In-house | ||||
| ONO-2808 | S1P5 receptor agonist | Neurodegenerative disease |
|
US | In-house | ||||
| ONO-7684 | FXIa inhibitor | Thrombosis |
|
US | In-house | ||||
| ONO-2910 | Enhancement of Schwann cell differentiation | Peripheral nerve disorder |
|
JP | In-house | ||||
| FOIPAN | Protease enzyme inhibitor | Novel coronavirus infection (COVID-19) |
|
JP | In-house | ||||